anti ngf prongf Search Results


sheep polyclonal anti prongf antibody  (Biosensis ltd)
94
Biosensis ltd sheep polyclonal anti prongf antibody
Fig. 2. Signaling through <t>proNGF–p75NTR,</t> but not mNGF–TrkA, is required for Gb3- induced mechanical sensitization. (A) Experimental timeline of the von Frey tests and the i.pl. injection of Gb3 and anti body/antiserum or antibody/antiserum alone. (B, C) The antiserum (1 μl/paw, i.pl.) containing anti-proNGF antibody effectively recovered the Gb3-induced decrease of the 50% paw withdrawal threshold (PWT; 1 h: H = 9.40, P = 0.009; 3 h: H = 9.13, P = 0.010; 6 h: H = 6.79, P = 0.034; 24 h: H = 6.24, P = 0.044) and its area under the curve (AUC; H = 10.1, P = 0.006). n = 8 per group. The injection volume was 10 μl. (D, E) The anti-NGF antibody (1 μg/paw and 10 μg/ paw, i.pl.) failed to significantly alleviate reductions in the pain threshold and its AUC (H = 10.5, P = 0.015) in Gb3-injected mice. Vehicle, n = 7; Gb3 + Control IgG, n = 8; Gb3 + Anti-NGF antibody (1 μg), n = 9; Gb3 + Anti-NGF antibody (10 μg), n = 6. The injection volume was 10 or 20 μl. (F, G) Administration of an anti-p75NTR antibody (1 μg/paw, i.pl.) almost completely reversed the Gb3-induced decline of the 50% PWT (24 h: H = 8.44, P = 0.015) and its AUC (H = 9.16, P = 0.010) to the level of the vehicle control. Vehicle, n = 11; Gb3 + Control IgG, n = 15; Gb3 + Anti-p75NTR antibody, n = 14. The injection volume was 10 or 20 μl. (H, I) Inhibition of TrkA activity with the neutral izing antibody (1 μg/paw and 10 μg/paw, i. pl.) gave minimal influence on the Gb3- induced mechanical allodynia (AUC: H = 9.80, P = 0.020). Vehicle, n = 11; Gb3 + Control IgG, n = 11; Gb3 + Anti-TrkA anti body (1 μg), n = 7; Gb3 + Anti-TrkA anti body (10 μg), n = 7. The injection volume was 20 μl. *P < 0.05, **P < 0.01 vs the Vehicle group, #P < 0.05, ##P < 0.01 vs the Gb3 + Normal serum or Control IgG group by Dunn’s test with Holm adjustment.
Sheep Polyclonal Anti Prongf Antibody, supplied by Biosensis ltd, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti+ngf+prongf/Anti-Pro-nerve+growth+factor+(proNGF)+Antibody/pm33482180-57-32-37
Average 94 stars, based on 1 article reviews
sheep polyclonal anti prongf antibody - by Bioz Stars, 2026-11
94/100 stars
  Buy from Supplier

Image Search Results


Fig. 2. Signaling through proNGF–p75NTR, but not mNGF–TrkA, is required for Gb3- induced mechanical sensitization. (A) Experimental timeline of the von Frey tests and the i.pl. injection of Gb3 and anti body/antiserum or antibody/antiserum alone. (B, C) The antiserum (1 μl/paw, i.pl.) containing anti-proNGF antibody effectively recovered the Gb3-induced decrease of the 50% paw withdrawal threshold (PWT; 1 h: H = 9.40, P = 0.009; 3 h: H = 9.13, P = 0.010; 6 h: H = 6.79, P = 0.034; 24 h: H = 6.24, P = 0.044) and its area under the curve (AUC; H = 10.1, P = 0.006). n = 8 per group. The injection volume was 10 μl. (D, E) The anti-NGF antibody (1 μg/paw and 10 μg/ paw, i.pl.) failed to significantly alleviate reductions in the pain threshold and its AUC (H = 10.5, P = 0.015) in Gb3-injected mice. Vehicle, n = 7; Gb3 + Control IgG, n = 8; Gb3 + Anti-NGF antibody (1 μg), n = 9; Gb3 + Anti-NGF antibody (10 μg), n = 6. The injection volume was 10 or 20 μl. (F, G) Administration of an anti-p75NTR antibody (1 μg/paw, i.pl.) almost completely reversed the Gb3-induced decline of the 50% PWT (24 h: H = 8.44, P = 0.015) and its AUC (H = 9.16, P = 0.010) to the level of the vehicle control. Vehicle, n = 11; Gb3 + Control IgG, n = 15; Gb3 + Anti-p75NTR antibody, n = 14. The injection volume was 10 or 20 μl. (H, I) Inhibition of TrkA activity with the neutral izing antibody (1 μg/paw and 10 μg/paw, i. pl.) gave minimal influence on the Gb3- induced mechanical allodynia (AUC: H = 9.80, P = 0.020). Vehicle, n = 11; Gb3 + Control IgG, n = 11; Gb3 + Anti-TrkA anti body (1 μg), n = 7; Gb3 + Anti-TrkA anti body (10 μg), n = 7. The injection volume was 20 μl. *P < 0.05, **P < 0.01 vs the Vehicle group, #P < 0.05, ##P < 0.01 vs the Gb3 + Normal serum or Control IgG group by Dunn’s test with Holm adjustment.

Journal: European journal of pharmacology

Article Title: Fabry disease-associated globotriaosylceramide induces mechanical allodynia via activation of signaling through proNGF-p75 NTR but not mature NGF-TrkA.

doi: 10.1016/j.ejphar.2021.173882

Figure Lengend Snippet: Fig. 2. Signaling through proNGF–p75NTR, but not mNGF–TrkA, is required for Gb3- induced mechanical sensitization. (A) Experimental timeline of the von Frey tests and the i.pl. injection of Gb3 and anti body/antiserum or antibody/antiserum alone. (B, C) The antiserum (1 μl/paw, i.pl.) containing anti-proNGF antibody effectively recovered the Gb3-induced decrease of the 50% paw withdrawal threshold (PWT; 1 h: H = 9.40, P = 0.009; 3 h: H = 9.13, P = 0.010; 6 h: H = 6.79, P = 0.034; 24 h: H = 6.24, P = 0.044) and its area under the curve (AUC; H = 10.1, P = 0.006). n = 8 per group. The injection volume was 10 μl. (D, E) The anti-NGF antibody (1 μg/paw and 10 μg/ paw, i.pl.) failed to significantly alleviate reductions in the pain threshold and its AUC (H = 10.5, P = 0.015) in Gb3-injected mice. Vehicle, n = 7; Gb3 + Control IgG, n = 8; Gb3 + Anti-NGF antibody (1 μg), n = 9; Gb3 + Anti-NGF antibody (10 μg), n = 6. The injection volume was 10 or 20 μl. (F, G) Administration of an anti-p75NTR antibody (1 μg/paw, i.pl.) almost completely reversed the Gb3-induced decline of the 50% PWT (24 h: H = 8.44, P = 0.015) and its AUC (H = 9.16, P = 0.010) to the level of the vehicle control. Vehicle, n = 11; Gb3 + Control IgG, n = 15; Gb3 + Anti-p75NTR antibody, n = 14. The injection volume was 10 or 20 μl. (H, I) Inhibition of TrkA activity with the neutral izing antibody (1 μg/paw and 10 μg/paw, i. pl.) gave minimal influence on the Gb3- induced mechanical allodynia (AUC: H = 9.80, P = 0.020). Vehicle, n = 11; Gb3 + Control IgG, n = 11; Gb3 + Anti-TrkA anti body (1 μg), n = 7; Gb3 + Anti-TrkA anti body (10 μg), n = 7. The injection volume was 20 μl. *P < 0.05, **P < 0.01 vs the Vehicle group, #P < 0.05, ##P < 0.01 vs the Gb3 + Normal serum or Control IgG group by Dunn’s test with Holm adjustment.

Article Snippet: The details of the NGF-related antibodies/antiserum and their control IgG/serum were as follows: mouse monoclonal anti-NGF antibody (L148M, Exalpha Biologicals, Shirley, MA, USA; 1 μg and 10 μg, Shutov et al., 2016); sheep polyclonal anti-proNGF antibody (S-080-100, Biosensis, Thebarton, Australia; 1 μl J. Sugimoto et al. European Journal of Pharmacology 895 (2021) 173882 antiserum); mouse monoclonal anti-TrkA antibody (Ab00439-1.4, Absolute Antibody, Redcar, UK; 1 μg and 10 μg, Ugolini et al., 2007); rabbit polyclonal anti-p75NTR antibody (AB-N01AP, Advanced Targeting Systems, San Diego, CA, USA; 1 μg, Watanabe et al., 2008); normal mouse IgG as a control of anti-NGF or anti-TrkA antibody (0G11, Exalpha Biologicals; Ab00178-1.4, Absolute Antibody); normal rabbit IgG as a control of anti-p75NTR antibody (PM035, MBL, Nagoya, Japan); and normal sheep serum as a control of anti-proNGF antibody (S3772, Sigma-Aldrich).

Techniques: Injection, Control, Inhibition, Activity Assay

Fig. 3. Gb3 injection did not lead to elevation of proNGF and mNGF or their receptor expression in either plantar skin or dorsal root ganglia. There were no changes in proNGF (A, C) nor mNGF (B, D) content in the plantar skin (A, B) and dorsal root ganglia (DRG; C, D) in mice that were 1 h or 24 h post-Gb3 treatment. n = 9 per group. The injection volume was 10 or 20 μl. Gb3 injection did not modify the expression levels of p75NTR in the plantar skin (E, 1 h: n = 6 per group; 24 h: n = 7 per group) or the DRG (F, n = 7 per group). The injection volume was 10 μl. The Vehicle (Veh) group, open circles; the Gb3 group, closed circles; MW, molecular weight.

Journal: European journal of pharmacology

Article Title: Fabry disease-associated globotriaosylceramide induces mechanical allodynia via activation of signaling through proNGF-p75 NTR but not mature NGF-TrkA.

doi: 10.1016/j.ejphar.2021.173882

Figure Lengend Snippet: Fig. 3. Gb3 injection did not lead to elevation of proNGF and mNGF or their receptor expression in either plantar skin or dorsal root ganglia. There were no changes in proNGF (A, C) nor mNGF (B, D) content in the plantar skin (A, B) and dorsal root ganglia (DRG; C, D) in mice that were 1 h or 24 h post-Gb3 treatment. n = 9 per group. The injection volume was 10 or 20 μl. Gb3 injection did not modify the expression levels of p75NTR in the plantar skin (E, 1 h: n = 6 per group; 24 h: n = 7 per group) or the DRG (F, n = 7 per group). The injection volume was 10 μl. The Vehicle (Veh) group, open circles; the Gb3 group, closed circles; MW, molecular weight.

Article Snippet: The details of the NGF-related antibodies/antiserum and their control IgG/serum were as follows: mouse monoclonal anti-NGF antibody (L148M, Exalpha Biologicals, Shirley, MA, USA; 1 μg and 10 μg, Shutov et al., 2016); sheep polyclonal anti-proNGF antibody (S-080-100, Biosensis, Thebarton, Australia; 1 μl J. Sugimoto et al. European Journal of Pharmacology 895 (2021) 173882 antiserum); mouse monoclonal anti-TrkA antibody (Ab00439-1.4, Absolute Antibody, Redcar, UK; 1 μg and 10 μg, Ugolini et al., 2007); rabbit polyclonal anti-p75NTR antibody (AB-N01AP, Advanced Targeting Systems, San Diego, CA, USA; 1 μg, Watanabe et al., 2008); normal mouse IgG as a control of anti-NGF or anti-TrkA antibody (0G11, Exalpha Biologicals; Ab00178-1.4, Absolute Antibody); normal rabbit IgG as a control of anti-p75NTR antibody (PM035, MBL, Nagoya, Japan); and normal sheep serum as a control of anti-proNGF antibody (S3772, Sigma-Aldrich).

Techniques: Injection, Expressing, Molecular Weight